These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 2422168

  • 1. Dopamine antagonist haloperidol decreases substance P, substance K, and preprotachykinin mRNAs in rat striatonigral neurons.
    Bannon MJ, Lee JM, Giraud P, Young A, Affolter HU, Bonner TI.
    J Biol Chem; 1986 May 25; 261(15):6640-2. PubMed ID: 2422168
    [Abstract] [Full Text] [Related]

  • 2. Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striato-nigral system.
    Humpel C, Knaus GA, Auer B, Knaus HG, Haring C, Theodorsson E, Saria A.
    Synapse; 1990 May 25; 6(1):1-9. PubMed ID: 1697986
    [Abstract] [Full Text] [Related]

  • 3. Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists.
    Bannon MJ, Elliott PJ, Bunney EB.
    Brain Res; 1987 Dec 25; 427(1):31-7. PubMed ID: 2448008
    [Abstract] [Full Text] [Related]

  • 4. Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway.
    Li SJ, Sivam SP, McGinty JF, Huang YS, Hong JS.
    J Pharmacol Exp Ther; 1987 Nov 25; 243(2):792-8. PubMed ID: 2445959
    [Abstract] [Full Text] [Related]

  • 5. Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs.
    Sivam SP, Krause JE, Takeuchi K, Li S, McGinty JF, Hong JS.
    J Pharmacol Exp Ther; 1989 Mar 25; 248(3):1297-301. PubMed ID: 2467980
    [Abstract] [Full Text] [Related]

  • 6. Dopaminergic regulation of striatonigral tachykinin and dynorphin gene expression: a study with the dopamine uptake inhibitor GBR-12909.
    Sivam SP.
    Brain Res Mol Brain Res; 1996 Jan 25; 35(1-2):197-210. PubMed ID: 8717356
    [Abstract] [Full Text] [Related]

  • 7. Effects of BDNF and NT-4/5 on striatonigral neuropeptides or nigral GABA neurons in vivo.
    Arenas E, Akerud P, Wong V, Boylan C, Persson H, Lindsay RM, Altar CA.
    Eur J Neurosci; 1996 Aug 25; 8(8):1707-17. PubMed ID: 8921261
    [Abstract] [Full Text] [Related]

  • 8. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A.
    Krause JE, Chirgwin JM, Carter MS, Xu ZS, Hershey AD.
    Proc Natl Acad Sci U S A; 1987 Feb 25; 84(3):881-5. PubMed ID: 2433692
    [Abstract] [Full Text] [Related]

  • 9. Expression of substance P/neurokinin A-encoding preprotachykinin messenger ribonucleic acids in the rat enteric nervous system.
    Sternini C, Anderson K, Frantz G, Krause JE, Brecha N.
    Gastroenterology; 1989 Aug 25; 97(2):348-56. PubMed ID: 2472998
    [Abstract] [Full Text] [Related]

  • 10. Tachykinins in the rat substantia nigra: effects of selective dopamine receptor antagonists.
    Oblin A, Zivkovic B.
    Fundam Clin Pharmacol; 1991 Aug 25; 5(2):129-38. PubMed ID: 1712746
    [Abstract] [Full Text] [Related]

  • 11. Intranigral injection of selective neurokinin-1 and neurokinin-3 but not neurokinin-2 receptor agonists biphasically modulate striatal dopamine metabolism but not striatal preprotachykinin-A mRNA in the rat.
    Humpel C, Saria A.
    Neurosci Lett; 1993 Jul 23; 157(2):223-6. PubMed ID: 7694197
    [Abstract] [Full Text] [Related]

  • 12. Tachykinin systems in the spinal cord and basal ganglia: influence of neonatal capsaicin treatment or dopaminergic intervention on levels of peptides, substance P-encoding mRNAs, and substance P receptor mRNA.
    Sivam SP, Krause JE.
    J Neurochem; 1992 Dec 23; 59(6):2278-84. PubMed ID: 1279124
    [Abstract] [Full Text] [Related]

  • 13. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression.
    Sivam SP, Breese GR, Krause JE, Napier TC, Mueller RA, Hong JS.
    J Neurochem; 1987 Nov 23; 49(5):1623-33. PubMed ID: 2889804
    [Abstract] [Full Text] [Related]

  • 14. Subchronic haloperidol treatment decreases the in vivo release of tachykinins in rat substantia nigra.
    Lindefors N, Brodin E, Ungerstedt U.
    Eur J Pharmacol; 1989 Feb 14; 161(1):95-8. PubMed ID: 2470596
    [Abstract] [Full Text] [Related]

  • 15. Serotonin-2 receptor stimulation normalizes striatal preprotachykinin messenger RNA in an animal model of Parkinson's disease.
    Gresch PJ, Walker PD.
    Neuroscience; 1999 Feb 14; 93(3):831-41. PubMed ID: 10473249
    [Abstract] [Full Text] [Related]

  • 16. The localization and characterization of substance P and substance K in striatonigral neurons.
    Lee JM, McLean S, Maggio JE, Zamir N, Roth RH, Eskay RL, Bannon MJ.
    Brain Res; 1986 Apr 16; 371(1):152-4. PubMed ID: 2423184
    [Abstract] [Full Text] [Related]

  • 17. Changes in substance P concentrations after protein synthesis inhibition provide an index of substance P utilization.
    Bannon MJ, Goedert M.
    Brain Res; 1984 May 28; 301(1):184-6. PubMed ID: 6203608
    [Abstract] [Full Text] [Related]

  • 18. Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing.
    Nawa H, Kotani H, Nakanishi S.
    Nature; 1984 May 28; 312(5996):729-34. PubMed ID: 6083453
    [Abstract] [Full Text] [Related]

  • 19. Simultaneous quantitation of substance P-encoding preprotachykinin alternatively spliced mRNAs and substance P receptor NK-1 mRNA by an RNase protection assay.
    Gautreau A, Kerdelhué B.
    Brain Res Brain Res Protoc; 1998 Jan 28; 2(2):133-40. PubMed ID: 9473630
    [Abstract] [Full Text] [Related]

  • 20. Regulation of striatonigral prodynorphin peptides by dopaminergic agents.
    Trujillo KA, Day R, Akil H.
    Brain Res; 1990 Jun 04; 518(1-2):244-56. PubMed ID: 1975215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.